Evidence map›Paper›PMID 31974712›Full record

ArticleAnnals of surgical oncology2020

Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.

Mariela Blum Murphy, Naruhiko Ikoma, Xuemei Wang, Jeannelyn Estrella, Sinchita Roy-Chowdhuri, Prajnan Das, Bruce D Minsky, Shumei Song, Paul Mansfield, Jaffer Ajani and 1 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mariela Blum MurphyDepartments of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Naruhiko IkomaDepartment of Surgical Oncology, Unit 1484, MD Anderson Cancer Center, Houston, TX, USA.
Xuemei WangDepartments of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
Jeannelyn EstrellaDepartments of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
Sinchita Roy-ChowdhuriDepartments of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
Prajnan DasDepartments of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Bruce D MinskyDepartments of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Shumei SongDepartments of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Paul MansfieldDepartment of Surgical Oncology, Unit 1484, MD Anderson Cancer Center, Houston, TX, USA.
Jaffer AjaniDepartments of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Brian BadgwellDepartment of Surgical Oncology, Unit 1484, MD Anderson Cancer Center, Houston, TX, USA. bbadgwell@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

backgroundThe purpose of this phase I trial is to evaluate the safety and toxicity of laparoscopic hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC), combining mitomycin, cisplatin, and paclitaxel for patients with gastric cancer metastatic to the peritoneum. PATIENTS AND

methodsA Bayesian optimal interval design was used to prospectively identify the safety and tolerability of escalating doses of paclitaxel in combination with flat doses of mitomycin (30 mg) and cisplatin (200 mg) during laparoscopic HIPEC. The primary objective is to define the maximum tolerated dose. Secondary endpoints include surgical complications and overall survival (OS).

resultsA total of 27 patients were treated between 11/2017 and 11/2018. No dose-limiting toxicities were observed. Treatment-related grade 1-2 toxicities were leukopenia (11%), oral dysesthesia (4%), arthralgia (4%), and diarrhea (4%). Treatment-related grade 3-4 toxicities included leukopenia (4%) and neutropenia (4%). The maximum dose for paclitaxel was 60 mg/m

conclusionsLaparoscopic HIPEC with mitomycin, cisplatin, and paclitaxel may be safely used at intraperitoneal doses of 30 mg, 200 mg, and 60 mg/m

Indexed as

AdenocarcinomaHyperthermia, InducedStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBayes TheoremCisplatinCombined Modality TherapyHumansMitomycinPaclitaxelPerfusionPeritoneal NeoplasmsCisplatinMitomycinPaclitaxel

Identifiers

PMID31974712
OpenAlexW3001087510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.